Blueprint Medicines Corporation (BPMC - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $75.71 –$86.60 in the past one-month time frame, witnessed a sharp increase on Friday.
The move came after the company announced the launch of a public offering of its common stock worth $300 million. It also accelerated the regulatory filling plans of its two key pipeline candidates — avapritinib and BLU-667.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Blueprint Medicines currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Blueprint Medicines Corporation Price
Investors interested in the Medical - Biomedical and Genetics industry may consider Celgene Corporation (CELG - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BPMC going up? Or down? Predict to see what others think:Up or Down
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>